Assessment of health risks resulting from early-life exposures: Are current chemical toxicity testing protocols and risk assessment methods adequate?

被引:33
作者
Felter, Susan P. [1 ]
Daston, George P. [1 ]
Euling, Susan Y. [2 ]
Piersma, Aldert H. [3 ]
Tassinari, Melissa S. [4 ]
机构
[1] Procter & Gamble Co, Cincinnati, OH 45217 USA
[2] US EPA, Natl Ctr Environm Assessment, Washington, DC 20460 USA
[3] Natl Inst Publ Hlth & Environm, NL-3720 BA Bilthoven, Netherlands
[4] US FDA, Ctr Drug Evaluat & Res, Washington, DC 20204 USA
关键词
children; development; infants; life stage; quantitative risk assessment; susceptibility; sensitivity; subpopulations; uncertainty factor; variability; vulnerability; DRUG-METABOLIZING-ENZYMES; REFERENCE DOSE RFD; HUMAN VARIABILITY; UNCERTAINTY FACTORS; DEVELOPMENTAL NEUROTOXICITY; IMMUNE-SYSTEM; PHARMACOKINETIC DIFFERENCES; DIFFERENTIAL SENSITIVITY; PERINATAL EXPOSURE; GENDER-DIFFERENCES;
D O I
10.3109/10408444.2014.993919
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
Over the last couple of decades, the awareness of the potential health impacts associated with early-life exposures has increased. Global regulatory approaches to chemical risk assessment are intended to be protective for the diverse human population including all life stages. However, questions persist as to whether the current testing approaches and risk assessment methodologies are adequately protective for infants and children. Here, we review physiological and developmental differences that may result in differential sensitivity associated with early-life exposures. It is clear that sensitivity to chemical exposures during early-life can be similar, higher, or lower than that of adults, and can change quickly within a short developmental time-frame. Moreover, age-related exposure differences provide an important consideration for overall susceptibility. Differential sensitivity associated with a life stage can reflect the toxicokinetic handling of a xenobiotic exposure, the toxicodynamic response, or both. Each of these is illustrated with chemical-specific examples. The adequacy of current testing protocols, proposed new tools, and risk assessment methods for systemic noncancer endpoints are reviewed in light of the potential for differential risk to infants and young children.
引用
收藏
页码:219 / 244
页数:26
相关论文
共 166 条
[1]   Changes in Individual Drug-Independent System Parameters during Virtual Paediatric Pharmacokinetic Trials: Introducing Time-Varying Physiology into a Paediatric PBPK Model [J].
Abduljalil, Khaled ;
Jamei, Masoud ;
Rostami-Hodjegan, Amin ;
Johnson, Trevor N. .
AAPS JOURNAL, 2014, 16 (03) :568-576
[2]   Implementing Toxicity Testing in the 21st Century (TT21C): Making safety decisions using toxicity pathways, and progress in a prototype risk assessment [J].
Adeleye, Yeyejide ;
Andersen, Melvin ;
Clewell, Rebecca ;
Davies, Michael ;
Dent, Matthew ;
Edwards, Sue ;
Fowler, Paul ;
Malcomber, Sophie ;
Nicol, Beate ;
Scott, Andrew ;
Scott, Sharon ;
Sun, Bin ;
Westmoreland, Carl ;
White, Andrew ;
Zhang, Qiang ;
Carmichael, Paul L. .
TOXICOLOGY, 2015, 332 :102-111
[3]   Physiological skin conditions of preterm and term neonates [J].
Afsar, F. S. .
CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2010, 35 (04) :346-350
[4]   Pharmacokinetics in the newborn [J].
Alcorn, J ;
McNamara, PJ .
ADVANCED DRUG DELIVERY REVIEWS, 2003, 55 (05) :667-686
[5]   Heterogeneity of toxicant response: Sources of human variability [J].
Aldridge, JE ;
Gibbons, JA ;
Flaherty, MM ;
Kreider, ML ;
Romano, JA ;
Levin, ED .
TOXICOLOGICAL SCIENCES, 2003, 76 (01) :3-20
[6]   Scientific Opinion on the hazard assessment of endocrine disruptors: Scientific criteria for identification of endocrine disruptors and appropriateness of existing test methods for assessing effects mediated by these substances on human health and the environment [J].
Alexander, Jan ;
Benford, Diane ;
Chaudhry, Qasim ;
Hardy, Anthony ;
Jeger, Michael John ;
Luttik, Robert ;
Martin, Ambroise ;
Ossendorp, Bernadette ;
More, Simon ;
Mortensen, Alicja ;
Noerrung, Birgit ;
Perry, Joe ;
Pratt, Iona ;
Sofos, John ;
Schlatter, Josef ;
Sejrsen, Kristen .
EFSA JOURNAL, 2013, 11 (03)
[8]   Developmental Pharmacokinetics [J].
Anderson, Gail D. .
SEMINARS IN PEDIATRIC NEUROLOGY, 2010, 17 (04) :208-213
[9]  
[Anonymous], LEAD TOX CAS STUD EN
[10]  
[Anonymous], 8706300 US EPA OPPTS